Genomic spectra of biliary tract cancer

Nature Genetics

Volumn 47, Issue 9, 2015, Pages 1003-1010

  Nakamura, Hiromi ^a   Arai, Yasuhito ^a   Totoki, Yasushi ^a   Shirota, Tomoki ^a,b   Elzawahry, Asmaa ^a   Kato, Mamoru ^a   Hama, Natsuko ^a   Hosoda, Fumie ^a   Urushidate, Tomoko ^c   Ohashi, Shoko ^a   Hiraoka, Nobuyoshi ^d   Ojima, Hidenori ^d,e   Shimada, Kazuaki ^d   Okusaka, Takuji ^d   Kosuge, Tomoo ^d   Miyagawa, Shinichi ^b   Shibata, Tatsuhiro ^a,c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AKT3 PROTEIN; APC PROTEIN; AT RICH INTERACTIVE DOMAIN 2; ATM PROTEIN; BAP1 PROTEIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ELF3 PROTEIN; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE DEMETHYLASE; HYDROLASE; ISOCITRATE DEHYDROGENASE 1; LYSINE K SPECIFIC DEMETHYLASE 5D; MITOGEN ACTIVATED PROTEIN KINASE; POLYBROMO 1 PROTEIN; PRKACA PROTEIN; PRKACB PROTEIN; PROTEIN; PROTEIN MDM2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RETINOBLASTOMA BINDING PROTEIN 2; UNCLASSIFIED DRUG; UTY PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; DNA BINDING PROTEIN; ELF3 PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; ONCOPROTEIN; PRKACA PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER GENETICS; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; EXTRAHEPATIC CHOLANGIOCARCINOMA; FRAMESHIFT MUTATION; GALLBLADDER CANCER; GENE DELETION; GENE FREQUENCY; GENE FUSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INDEL MUTATION; MISMATCH REPAIR; MISSENSE MUTATION; MOUSE; MUTATION RATE; NONHUMAN; NONSENSE MUTATION; ONCOGENE K RAS; ONCOGENE MYC; ONCOGENE N RAS; POINT MUTATION; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNINDEXED SEQUENCE; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; WART VIRUS; BILIARY TRACT TUMOR; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOMICS; NUCLEOTIDE SEQUENCE; PROGNOSIS;

BILIARY TRACT NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNITS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; ONCOGENE PROTEINS, FUSION; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TRANSCRIPTION FACTORS;

EID: 84940556535     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3375     Document Type: Article

References (42)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Patel, T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002).
3. Tyson, G.L. & El-Serag, H.B. Risk factors for cholangiocarcinoma. Hepatology 54, 173-184 (2011).
4. Rizvi, S. & Gores, G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145, 1215-1229 (2013).
5. Razumilava, N. & Gores, G.J. Cholangiocarcinoma. Lancet 383, 2168-2179 (2014).
6. Misra, S., Chaturvedi, A., Misra, N.C. & Sharma, I.D. Carcinoma of the gallbladder. Lancet Oncol. 4, 167-176 (2003).
7. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
8. Chan-On, W. et al. Exome sequencing identifes distinct mutational patterns in liver fuke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474-1478 (2013).
9. Li, M. et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifes recurrent mutations in the ErbB pathway. Nat. Genet. 46, 872-876 (2014).
10. Wu, Y.M. et al. Identifcation of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647 (2013).
11. Arai, Y. et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions defne a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427-1434 (2014).
12. Honeyman, J.N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fbrolamellar hepatocellular carcinoma. Science 343, 1010-1014 (2014).
13. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
14. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310-1316 (1999).
15. Pilarski, R. et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosom. Cancer 53, 177-182 (2014).
16. Saha, S.K. et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513, 110-114 (2014).
17. Totoki, Y. et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273 (2014).
18. Ojesina, A.I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2014).
19. Chen, C.R., Kang, Y., Siegel, P.M. & Massagué, J. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell 110, 19-32 (2002).
20. Shi, J. et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 27, 2648-2662 (2013).
21. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
22. Tumeh, P.C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
23. Burns, M.B., Temiz, N.A. & Harris, R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977-983 (2013).
24. Beuschlein, F. et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N. Engl. J. Med. 370, 1019-1028 (2014).
25. Kirschner, L.S. et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet. 26, 89-92 (2000).
26. Huch, M. et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160, 299-312 (2015).
27. de Visser, K.E., Eichten, A. & Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37 (2006).
28. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
29. Rizvi, N.A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
30. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012).
31. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
32. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
33. Mermel, C.H. et al. GISTIC2.0 facilitates sensitive and confdent localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
34. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004).
35. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-effcient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
36. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
37. Alexandrov, L.B. et al. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
38. Brunet, J.P. et al. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. USA 101, 4164-4169 (2004).
39. Babur, Ö. et al. Systematic identifcation of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol. 16, 45 (2015).
40. Leiserson, M.D., Blokh, D., Sharan, R. & Raphael, B.J. Simultaneous identifcation of multiple driver pathways in cancer. PLOS Comput. Biol. 9, e1003054 (2013).
41. Mo, Q. et al. Pattern discovery and cancer gene identifcation in integrated cancer genomic data. Proc. Natl. Acad. Sci. USA 110, 4245-4250 (2013).
42. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).